FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach. “This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,” said Pete O’Heeron, Founder & Chief Executive Officer of FibroBiologics. “Our technology leverages the unique capabilities of fibroblasts to target immune dysregulation, underscoring their promise in treating complex conditions linked to immune system dysfunction.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics files patent application on reduction of clots related to IBMIR
- FibroBiologics Reports Q3 2024 Financial Results
- Alphabet upgraded, Boeing downgraded: Wall Street’s top analyst calls
- FibroBiologics initiated with a Buy at H.C. Wainwright
- FibroBiologics Announces Leadership Changes and New Appointments